The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma (Q44392521)
Jump to navigation
Jump to search
scientific article published on 9 November 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma |
scientific article published on 9 November 2013 |
Statements
1 reference
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma (English)
1 reference
1 reference
1 reference
Yung-Lin Chang
1 reference
Chung-Yi Huang
1 reference
9 November 2013
1 reference
1 reference
85
1 reference
5
1 reference
312-316
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference